Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Current Assets (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Current Assets readings, the most recent being $45.3 million for Q4 2022.

  • On a quarterly basis, Current Assets fell 34.53% to $45.3 million in Q4 2022 year-over-year; TTM through Dec 2022 was $45.3 million, a 34.53% decrease, with the full-year FY2022 number at $45.3 million, down 34.53% from a year prior.
  • Current Assets hit $45.3 million in Q4 2022 for Cardiol Therapeutics, down from $52.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $69.1 million in Q4 2021 to a low of $11.5 million in Q4 2020.
  • Median Current Assets over the past 3 years was $48.6 million (2022), compared with a mean of $43.9 million.
  • Biggest five-year swings in Current Assets: skyrocketed 502.85% in 2021 and later plummeted 34.53% in 2022.
  • Cardiol Therapeutics' Current Assets stood at $11.5 million in 2020, then skyrocketed by 502.85% to $69.1 million in 2021, then plummeted by 34.53% to $45.3 million in 2022.
  • The last three reported values for Current Assets were $45.3 million (Q4 2022), $52.0 million (Q3 2022), and $57.7 million (Q2 2022) per Business Quant data.